Physician profile
Ruchir Gupta
NPI 1265668453
$14,839.30
in general payments reported to CMS, 2019-2025
28 companies · $5,131 in 2025
The $5,131 reported for 2025 was more than what 93% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.93 · 2020: $692 · 2021: $2,482 · 2022: $1,571 · 2023: $1,966 · 2024: $2,981 · 2025: $5,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,158 · Debt Forgiveness: $1,914 · Travel and Lodging: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,157.81 |
| Debt Forgiveness | $1,914.08 |
| Travel and Lodging | $1,005.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,083.75 | 2021-2025 | Proclaim, Eterna, Octrode |
| Medtronic, INC. | $1,946.39 | 2021-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Merit Medical Systems INC | $1,914.08 | 2025 | |
| Si-Bone, INC. | $824.24 | 2021-2024 | |
| Nalu Medical, INC. | $770.37 | 2023-2025 | Nalu Neurostimulation System |
| Nevro Corp. | $729.77 | 2020-2023 | Senza |
| Medtronic USA, INC. | $432.75 | 2020 | |
| Abbvie INC. | $186.40 | 2022-2025 | |
| Averitas Pharma INC. | $154.42 | 2023-2024 | Qutenza |
| Arteriocyte Medical Systems, INC. | $109.52 | 2023 | Magellan |
| Boston Scientific Corporation | $102.35 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Spr Therapeutics, INC | $96.79 | 2021-2024 | Sprint Pns System |
| Electronic Waveform Lab, INC. | $85.80 | 2022-2025 | |
| Nuvasive, INC. | $79.27 | 2021 | |
| Stryker Corporation | $56.96 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.03 | 2024-2025 | Spravato, Xarelto |
| Saluda Medical Americas, INC. | $30.97 | 2024 | Evoke |
| Lilly USA, LLC | $28.40 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.05 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.71 | 2020 | |
| Brainsway USA INC | $22.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.53 | 2023 | Seglentis |
| Chiesi USA, INC. | $15.93 | 2019 | |
| Globus Medical, INC. | $15.30 | 2025 | Senza |
| Allergan, INC. | $15.16 | 2022 | |
| Bioventus LLC | $14.78 | 2022 | |
| Lundbeck LLC | $12.40 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchir Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.